Chest Medicine (all articles)
Perspective | We’re Asking the Impossible of Vaccines – “Complete protection against infection has long been hailed as the holy grail of vaccination. It might simply be unachievable”.
12 Sep, 2021 | 21:59h | UTCWe’re Asking the Impossible of Vaccines – The Atlantic
Commentary on Twitter
A really great read from @KatherineJWu on why it may be too much to expect vaccines—#covid19 or otherwise—to prevent infection. Still the vaccines are great at what we need—preventing hospitalizations and deaths! https://t.co/ufVBVn4wd1
— Jennifer Nuzzo, DrPH (@JenniferNuzzo) September 11, 2021
Risk of severe breakthrough Covid-19 higher for seniors and people with underlying conditions.
12 Sep, 2021 | 22:03h | UTCRisk of severe breakthrough Covid-19 higher for seniors and people with underlying conditions – CNN
Original study: Hospitalisation among vaccine breakthrough COVID-19 infections – The Lancet Infectious Diseases
News release: Study examines severe breakthrough cases of COVID-19 – YaleNews
Commentary on Twitter
New Comment: Hospitalisation among vaccine breakthrough #COVID19 infections https://t.co/1MtOoO8HVV, by Prerak V Juthani, @hyungjchun, and colleagues pic.twitter.com/mYAAEzHLDL
— The Lancet Infectious Diseases (@TheLancetInfDis) September 8, 2021
Extracorporeal cardiopulmonary resuscitation in adults: evidence and implications.
12 Sep, 2021 | 21:46h | UTC
Commentary on Twitter
#ECPR in adults: data from recent RCTs offer rigorous evidence that may improve survival with neuro & functional recovery when performed within highly coordinated systems. Do not forget ethical/economic implications that may accompany more widespread use. https://t.co/DCyDHomJB8 pic.twitter.com/NLz1sQNf6V
— Intens Care Med (@yourICM) September 10, 2021
RCT: Convalescent plasma does not improve outcomes and may be harmful to hospitalized patients with COVID-19.
10 Sep, 2021 | 05:37h | UTCNews release: Major study finds convalescent plasma doesn’t help seriously ill COVID-19 patients – McMaster University
Related:
M-A: Convalescent plasma is safe but does not improve outcomes in the treatment of COVID-19.
RECOVERY Trial: No benefit from convalescent plasma in patients admitted to hospital with COVID-19.
Commentary on Twitter
A randomized trial in patients hospitalized with COVID-19 showed no benefit and potentially increased harm associated with the use of convalescent plasma, according to a @NatureMedicine paper. https://t.co/7JFhEXLmbA pic.twitter.com/Q3e50Q0I7T
— Nature Portfolio (@NaturePortfolio) September 9, 2021
Face masks for COVID pass their largest test yet – “A rigorous study finds that surgical masks are highly protective, but cloth masks fall short”.
10 Sep, 2021 | 05:36h | UTCFace masks for COVID pass their largest test yet – Nature
Original study: [Preprint] Largest study of masks yet details their importance in fighting Covid-19.
Commentary on Twitter
Face masks for COVID pass their largest test yet – I & others comment. It is true that I bought pink surgical masks (my favorite color) in response to this study for when I am around unvaccinated adults (or indoor public spaces for now)https://t.co/nFhlcqwrjv
— Monica Gandhi MD, MPH (@MonicaGandhi9) September 9, 2021
Covid-19: Infection increases the risk of kidney disease even in mild cases, finds study.
10 Sep, 2021 | 05:33h | UTCCovid-19: Infection increases the risk of kidney disease even in mild cases, finds study – The BMJ
Original study: Kidney Outcomes in Long COVID – Journal of the American Society of Nephrology
Long COVID and kidney disease.
10 Sep, 2021 | 05:31h | UTCLong COVID and kidney disease – Nature Reviews Nephrology
COVID infections may give more potent immunity than vaccines – but that doesn’t mean you should try to catch it.
10 Sep, 2021 | 05:29h | UTCOriginal study and commentary: [Preprint] Observational data suggests natural immunity after a SARS-CoV-2 infection confers longer lasting and stronger protection compared to vaccine-induced immunity.
Perspective | What we actually know about waning immunity.
10 Sep, 2021 | 05:26h | UTCWhat We Actually Know About Waning Immunity – The Atlantic
Topic-based, recent literature review on pulmonary hypertension.
10 Sep, 2021 | 05:06h | UTCTopic-Based, Recent Literature Review on Pulmonary Hypertension – Mayo Clinic Proceedings
[Preprint] Ineffective neutralization of the SARS-CoV-2 Mu variant by convalescent and vaccine sera.
9 Sep, 2021 | 10:02h | UTCIneffective neutralization of the SARS-CoV-2 Mu variant by convalescent and vaccine sera – bioRxiv
Related: United States boosts tracking of coronavirus strains as Mu variant draws scrutiny – Science
Commentary on Twitter (thread – click for more)
?Bad news on #MuVariant—Japanese scientists: "Mu variant is highly resistant to sera from convalescent & [Pfizer]-vaccinated people. Direct comparison of different spike proteins revealed that Mu spike is more resistant…than all other current variants”?https://t.co/Ilf5gh3OGd pic.twitter.com/DbdJVGZTjz
— Eric Feigl-Ding (@DrEricDing) September 8, 2021
[Preprint] RCT: Additional heterologous vs. homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination.
9 Sep, 2021 | 09:55h | UTC
Commentary on Twitter (thread – click for more)
Results of 60-person randomized trial of 3rd shot of mRNA or AZ vax in people on rituximab who didn't seroconvert after BNT-Pfizer (most) or Moderna vax. Found dose 3 reduced those with no humoral or cellular response from 31% to 6% …1/2 https://t.co/HIjeDaFy7w Preprint #IC
— Hilda Bastian, PhD (@hildabast) September 8, 2021
AstraZeneca bosses warn against rush for boosters – “giving the most vulnerable, who may not have built up a full immune response from the first two, a third, top-up dose is “sensible”. But any decision to give a third, booster jab “to large swathes of the population”, to extend their protection from the first two, must be based on clinical data”.
9 Sep, 2021 | 09:59h | UTCAstraZeneca bosses warn against rush for boosters – BBC
Commentary on Twitter (thread – click for more)
"Moving too quickly to boost across the entire adult population will deprive us of these insights, leaving this important decision to rest on limited data," Mr Soriot and Sir Mene write.https://t.co/xTAk7yyu5G
— The Sharing Scientist (@ScienceShared) September 8, 2021
Perspective | The plan to stop every respiratory virus at once – “The benefits of ventilation reach far beyond the coronavirus. What if we stop taking colds and flus for granted, too?”
9 Sep, 2021 | 09:54h | UTCThe Plan to Stop Every Respiratory Virus at Once – The Atlantic
Related:
Recommendations for ventilation of indoor spaces to reduce COVID-19 transmission.
We studied how to reduce airborne COVID spread in hospitals. Here’s what we learnt.
WHO: Roadmap to improve and ensure good indoor ventilation in the context of COVID-19
CDC releases new ventilation guidelines for indoor environments to reduce Covid-19 risk
A large observational study suggests eating a plant-rich diet could reduce the risk of developing severe COVID-19.
9 Sep, 2021 | 09:51h | UTCEating a plant rich diet reduces risk of developing COVID-19 – King’s College London
Original study: Diet quality and risk and severity of COVID-19: a prospective cohort study – Gut
RCT: No benefit from Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis.
9 Sep, 2021 | 08:59h | UTCCyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomised, double-blind, placebo-controlled, phase 3 trial – The Lancet Respiratory Medicine (link to abstract – $ for full-text)
Spread of Delta SARS-CoV-2 variant driven by a combination of immune escape and increased infectivity.
7 Sep, 2021 | 21:49h | UTCOriginal article: SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion – Nature
Cochrane review: evidence is insufficient to draw meaningful conclusions if SARS‐CoV‐2-specific monoclonal antibodies are effective in the treatment of COVID-19.
7 Sep, 2021 | 21:51h | UTCOriginal review: SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 – Cochrane Library
[Preprint] M-A of 12.011.447 individuals finds individuals previously infected with SARS-CoV-2 had an 81% reduction in odds of a reinfection.
7 Sep, 2021 | 21:42h | UTC
Commentary on Twitter
A new systematic review of over 12 million people from 54 studies at up to 8 months following Covid. >90% prevalence of IgG antibodies, reinfection 0.2% (an 81% risk reduction) https://t.co/ljir4DV1zU ("did not examine evidence for immunity against the new variants") pic.twitter.com/pT7A2KA9FV
— Eric Topol (@EricTopol) September 7, 2021
Supplement: Current Issues in Venous Thromboembolism.
7 Sep, 2021 | 21:36h | UTCHomepage: Current Issues in Venous Thromboembolism – Postgraduate Medicine
Editorial: Current issues in venous thromboembolism
A review of upper extremity deep vein thrombosis
Outpatient treatment of emergency department patients diagnosed with venous thromboembolism
Venous thromboembolism prophylaxis in high-risk orthopedic and cancer surgery
Prophylaxis and treatment of COVID-19 related venous thromboembolism
Challenges in the diagnostic approach of suspected pulmonary embolism in COVID-19 patients
Post-hospital discharge venous thromboembolism prophylaxis in medically ill patients
Radiologic mimics of pulmonary embolism
A comprehensive review of DOACs for cancer associated VTE prophylaxis or treatment
The Lancet Series: Interstitial Lung Disease 2021.
7 Sep, 2021 | 21:37h | UTCHomepage: Interstitial Lung Disease 2021 (free registration required for all articles)
Early diagnosis of fibrotic interstitial lung disease: challenges and opportunities
Treatment of fibrotic interstitial lung disease: current approaches and future directions
Interstitial lung diseases: quo vadis?
Moving beyond usual interstitial pneumonia to define progressive fibrotic interstitial lung disease
Commentary on Twitter (thread – click for more)
? The term interstitial lung disease (ILD) refers to a diverse group of inflammatory & fibrotic conditions—with fibrotic ILD being a disease subset that constitutes a major global health problem.
Read the new @TheLancet & @LancetRespirMed Series. https://t.co/zV2Vw2l4rV pic.twitter.com/AqAe4GUlmr
— The Lancet (@TheLancet) September 7, 2021
Isn’t it time to abandon ARDS? The COVID-19 lesson.
7 Sep, 2021 | 21:34h | UTCIsn’t it time to abandon ARDS? The COVID-19 lesson – Critical Care
Commentary on Twitter
#CritCare #OA #Gattinoni & #Marini: Keeping or abandoning #ARDS?
▶️ pros
▶️ conshttps://t.co/tIhusXT2S7#FOAMed #FOAMcc #BMC #COVID19 #Rx #RCT #PEEP #respiratory_failure #Personalized pic.twitter.com/M6aoiSAn3m— Critical Care (@Crit_Care) September 7, 2021
Extended intervals and extra doses of the AstraZeneca vaccine are associated with increased immunogenicity.
7 Sep, 2021 | 10:56h | UTCInvited commentary: Longer intervals and extra doses of ChAdOx1 nCoV-19 vaccine
Commentaries on Twitter
(thread – click for more)
Substudy suggests extended interval (up to 45 wks) before 2nd dose of ChAdOx1 nCoV-19 leads to increased antibody titres, offering more flexibility in vaccine schedules.
Extended interval before 3rd dose resulted in further increase in immune responses. https://t.co/J3xOwSSYMN pic.twitter.com/8GotDI4ctS
— The Lancet (@TheLancet) September 2, 2021
(thread – click for more)
New @TheLancet
The heightened immune response to longer spacing @AstraZeneca 1st -> 2nd vaccine doses and the response 3rd booster dose, with high neutralizing antibodies and T cellshttps://t.co/A2UcPVIFYP pic.twitter.com/zfYaW0T8Yf— Eric Topol (@EricTopol) September 1, 2021
[Preprint] Large cohort study in Brazil showed AstraZeneca vaccine had high overall effectiveness against severe disease to individuals up to 89 years of age. In comparison, CoronaVac had high overall effectiveness against severe disease in individuals up to 79 years.
7 Sep, 2021 | 10:54h | UTC
Annual Update in Intensive Care and Emergency Medicine 2021 – Covid articles.
7 Sep, 2021 | 10:50h | UTCSecondary infections in critically ill patients with COVID-19
Tracheostomy for COVID-19: evolving best practice
See also: Non-Covid articles